{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:51:03Z","timestamp":1791265863457,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07973-5","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:51:14Z","timestamp":1791262274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baxdrostat in Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2290-605X","authenticated-orcid":false,"given":"Adir","family":"Alper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Fagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Faillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"7973_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134:441\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018912.","journal-title":"Circulation"},{"key":"7973_CR2","doi-asserted-by":"publisher","unstructured":"GBD 2023 Cardiovascular Disease Collaborators Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023. J Am Coll Cardiol. 2025;0735\u201310972507428. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.015.","DOI":"10.1016\/j.jacc.2025.08.015"},{"key":"7973_CR3","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:e127\u2013248. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.006","journal-title":"J Am Coll Cardiol"},{"key":"7973_CR4","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"key":"7973_CR5","doi-asserted-by":"publisher","unstructured":"Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72. https:\/\/doi.org\/10.1161\/HYP.0000000000000084.","DOI":"10.1161\/HYP.0000000000000084"},{"key":"7973_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.114.03231","volume":"63","author":"JM Brown","year":"2014","unstructured":"Brown JM, Underwood PC, Ferri C, et al. Aldosterone Dysregulation With Aging Predicts Renal Vascular Function and Cardiovascular Risk. Hypertension. 2014;63:1205\u201311. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03231.","journal-title":"Hypertension"},{"key":"7973_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown JM, Siddiqui M, Calhoun DA, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020;173:10\u201320. https:\/\/doi.org\/10.7326\/M20-0065.","journal-title":"Ann Intern Med"},{"key":"7973_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7973_CR9","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK. Characterization of Resistant HypertensionAssociation Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion. Arch Intern Med. 2008;168:1159. https:\/\/doi.org\/10.1001\/archinte.168.11.1159.","journal-title":"Arch Intern Med"},{"key":"7973_CR10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3.","journal-title":"Lancet"},{"key":"7973_CR11","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","volume":"24","author":"MS Kallistratos","year":"2019","unstructured":"Kallistratos MS, Pittaras A, Theodoulidis I, et al. Adverse Effects of Mineralocorticoid Receptor Antagonist Administration. CPD. 2019;24:5537\u201341. https:\/\/doi.org\/10.2174\/1381612825666190222144359.","journal-title":"CPD"},{"key":"7973_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709\u201316. https:\/\/doi.org\/10.1016\/S0895-7061(02)02957-6.","journal-title":"Am J Hypertens"},{"key":"7973_CR13","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","volume":"110","author":"M Azizi","year":"2025","unstructured":"Azizi M, Riancho J, Amar L. Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases. J Clin Endocrinol Metabolism. 2025;110:e557\u201365. https:\/\/doi.org\/10.1210\/clinem\/dgae823.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"7973_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ndt\/gfs388","volume":"28","author":"M Azizi","year":"2013","unstructured":"Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dialysis Transplantation. 2013;28:36\u201343. https:\/\/doi.org\/10.1093\/ndt\/gfs388.","journal-title":"Nephrol Dialysis Transplantation"},{"key":"7973_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","volume":"69","author":"K Bogman","year":"2017","unstructured":"Bogman K, Schwab D, Delporte M-L, et al. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension. 2017;69:189\u201396. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07716.","journal-title":"Hypertension"},{"key":"7973_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020;8:748\u201361. https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7973_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, et al. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46:108\u201318. https:\/\/doi.org\/10.1038\/s41440-022-01070-4.","journal-title":"Hypertens Res"},{"key":"7973_CR18","doi-asserted-by":"publisher","first-page":"1097968","DOI":"10.3389\/fendo.2022.1097968","volume":"13","author":"I Forzano","year":"2022","unstructured":"Forzano I, Mone P, Varzideh F, et al. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension. Front Endocrinol. 2022;13:1097968. https:\/\/doi.org\/10.3389\/fendo.2022.1097968.","journal-title":"Front Endocrinol"},{"key":"7973_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen Y-D, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388:395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2213169.","journal-title":"N Engl J Med"},{"key":"7973_CR20","unstructured":"Dharam KHALO. baxdrostat in patients with uncontrolled hypertension. Presented at: ACC 2023; New Orleans, LA; March 4\u20136, 2023."},{"key":"7973_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","volume":"407","author":"M Azizi","year":"2026","unstructured":"Azizi M, Brown JM, Dwyer JP, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407:988\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(25)02549-8.","journal-title":"Lancet"},{"key":"7973_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393:1363\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2507109.","journal-title":"N Engl J Med"},{"key":"7973_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","volume":"37","author":"JP Dwyer","year":"2026","unstructured":"Dwyer JP, Maklad N, Vedin O, et al. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. JASN. 2026;37:299\u2013311. https:\/\/doi.org\/10.1681\/ASN.0000000849.","journal-title":"JASN"},{"key":"7973_CR24","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"7973_CR25","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"7973_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015.","journal-title":"J Clin Epidemiol"},{"key":"7973_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"7973_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. Am J Med. 2009;122:290\u2013300. https:\/\/doi.org\/10.1016\/j.amjmed.2008.09.038.","journal-title":"Am J Med"},{"key":"7973_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(15)01225-8.","journal-title":"Lancet"},{"key":"7973_CR30","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/heartjnl-2014-305540","volume":"100","author":"MJ Brown","year":"2014","unstructured":"Brown MJ. Resistant hypertension: resistance to treatment or resistance to taking treatment? Heart. 2014;100:821\u20132. https:\/\/doi.org\/10.1136\/heartjnl-2014-305540.","journal-title":"Heart"},{"key":"7973_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543\u201351. https:\/\/doi.org\/10.1056\/NEJMoa040135.","journal-title":"N Engl J Med"},{"key":"7973_CR32","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation. 2022;145:1460\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057736.","journal-title":"Circulation"},{"key":"7973_CR33","doi-asserted-by":"publisher","first-page":"8751","DOI":"10.2174\/0109298673348789250604113545","volume":"32","author":"P Tsioufis","year":"2025","unstructured":"Tsioufis P, Theofilis P, Dimitriadis K, et al. Inflammatory Biomarkers in Hypertension. Curr Med Chem. 2025;32:8751\u201364. https:\/\/doi.org\/10.2174\/0109298673348789250604113545.","journal-title":"Curr Med Chem"},{"key":"7973_CR34","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3390\/biomedicines13081951","volume":"13","author":"P Iliakis","year":"2025","unstructured":"Iliakis P, Dimitriadis K, Tatakis F, et al. Safety and Efficacy of Renal Denervation for the Treatment of Resistant Hypertension in Patients with Chronic Kidney Disease: A Narrative Review of the Literature. Biomedicines. 2025;13:1951. https:\/\/doi.org\/10.3390\/biomedicines13081951.","journal-title":"Biomedicines"},{"key":"7973_CR35","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.119.14659","volume":"75","author":"D Collard","year":"2020","unstructured":"Collard D, Brouwer TF, Olde Engberink RHG, et al. Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy: a post hoc analysis of the SPRINT and ACCORD-BP randomized controlled. Trials Hypertens. 2020;75:1205\u201312. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14659","journal-title":"Trials Hypertens"},{"key":"7973_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1681\/ASN.2021070948","volume":"33","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Tighiouart H, Heerspink HJL, et al. Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. JASN. 2022;33:291\u2013303. https:\/\/doi.org\/10.1681\/ASN.2021070948.","journal-title":"JASN"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07973-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:51:21Z","timestamp":1791262281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":36,"alternative-id":["7973"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07973-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a review study of published RCTs; IRB was not pursued per guidelines.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}